Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

(2011) Eric Lawitz et al.   ANTIVIRAL RESEARCH

Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025

(2010) Isabelle Landrieu et al.   BIOCHEMISTRY

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors

(2010) Udayan Chatterji et al.   JOURNAL OF HEPATOLOGY

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle

(2009) Dirk Daelemans et al.   ANTIVIRAL RESEARCH

Cyclophilin Inhibitors

(2009) Philippe A. Gallay   Clinics in Liver Disease

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

(2009) Raf Crabbé et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

(2009) Udayan Chatterji et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex

(2009) Z. Liu et al.   JOURNAL OF VIROLOGY

Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type

(2009) Saori Matsuoka et al.   Retrovirology

Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

(2009) Artur Kaul et al.   PLoS Pathogens

Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent

(2008) R. G. Ptak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors

(2008) L. Coelmont et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

(2008) Robert Flisiak et al.   HEPATOLOGY

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

(2008) F. Yang et al.   JOURNAL OF VIROLOGY